Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has c... Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. Show more
Ask ADVFN Intelligence (AI)
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors PR Newswire ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 ROCKVILLE, Md. and SUZHOU...
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on...
SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...
OP-3136, a potent KAT6 inhibitor, demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND submission...
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.33 | -13.1552917903 | 10.11 | 10.19 | 7.675 | 687045 | 8.4292145 | CS |
| 4 | -2.99 | -25.4035683942 | 11.77 | 13.51 | 7.675 | 489080 | 10.60372085 | CS |
| 12 | -2.88 | -24.6998284734 | 11.66 | 13.93 | 7.675 | 469726 | 11.69741116 | CS |
| 26 | -0.56 | -5.99571734475 | 9.34 | 16.62 | 7.675 | 684520 | 12.3249433 | CS |
| 52 | -5.48 | -38.4291725105 | 14.26 | 16.775 | 7.675 | 781071 | 12.26226392 | CS |
| 156 | -13.97 | -61.4065934066 | 22.75 | 25.7 | 2 | 511820 | 9.87555463 | CS |
| 260 | -38.22 | -81.3191489362 | 47 | 60.27 | 2 | 443048 | 12.80013299 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
